BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33831245)

  • 1. Pancreas cancer: Therapeutic trials in metastatic disease.
    Smithy JW; O'Reilly EM
    J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    Singh RR; O'Reilly EM
    Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
    Tesfaye AA; Kamgar M; Azmi A; Philip PA
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Treatment Strategies in Pancreatic Cancer.
    Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
    Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
    Adamska A; Domenichini A; Falasca M
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
    Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
    Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for pancreatic ductal adenocarcinoma.
    Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
    J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.
    Stone ML; Beatty GL
    Pharmacol Ther; 2019 Sep; 201():202-213. PubMed ID: 31158393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation therapies for pancreatic cancer.
    Buckley CW; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
    Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
    Front Immunol; 2018; 9():1044. PubMed ID: 29868007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
    Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
    Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
    RĂ©mond MS; Pellat A; Brezault C; Dhooge M; Coriat R
    ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
    Manji GA; Olive KP; Saenger YM; Oberstein P
    Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.